EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study

Maike M Holtsche iD, Nina van Beek, Christoph M Hammers, Artem Vorobyev iD, Michael Kasperkiewicz, Nina Schumacher, Philip Muck, Enno Schmidt

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.15909 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Maike M Holtsche und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University of Lübeck, Lübeck, Germany. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Immunosorbent Techniques. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives Bullous pemphigoid (BP) is the most common autoimmune blistering disease in the Western world. While remission is achieved in the majority of BP patients by long‐term use of corticosteroids with or without immunomodulants/immunosuppressants, national and international guidelines recommend adjuvant immunoadsorption (IA) in refractory patients. Here we investigated the safety and efficacy of IA in severe and/or refractory BP patients. Patients and Methods 10 BP patients (3 women, 7 men; mean age 69.7 years; range 52–81 years) were treated with IA on three consecutive days (LigaSorb ® , Fresenius Medical Care) combined with oral prednisolone (0.5 mg/kg BW per day, tapered), dapsone (1.5 mg/kg BW per day), and lesional mometasone furoate ointment.

Results

Within 2 and 6 months after IA, 50% and 90% of patients showed complete remission on therapy, respectively. In all patients, serum anti‐BP180 IgG levels decreased significantly by an average of 89% and 73% immediately after the third IA and 4 weeks later, respectively. A total of 56 adverse events (AE) occurred during the 12‐month follow‐up. The majority of AE were of severity grade 2 (50%), 15 AE were classified as severe (grade 3–4).

Conclusions

IA can be considered as a relatively safe and effective adjuvant therapy for patients with severe or refractory BP.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousImmunosorbent TechniquesHumansFemaleMaleAgedAged, 80 and overPilot ProjectsMiddle AgedTreatment OutcomeProspective StudiesCombined Modality TherapyPrednisoloneDapsoneChemotherapy, AdjuvantImmunosuppressive Agents

Stichwörter der Autor:innen

BP180autoimmune blistering diseasebullous pemphigoidimmunoadsorption

Substanzen

PrednisoloneDapsoneImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Dermatology, University of Lübeck, Lübeck, Germany.
  • Department of Dermatology, University of Oldenburg, Oldenburg, Germany.
  • Division of Dermatology, Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, USA.
  • Department of Internal Medicine, University of Lübeck, Lübeck, Germany.
  • Lübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany.

ORCID-Profile: Maike M Holtsche, Artem Vorobyev

Zitieren

APA

Holtsche, M. M., van Beek, N., Hammers, C. M., Vorobyev, A., Kasperkiewicz, M., Schumacher, N., Muck, P., & Schmidt, E. (2026). Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15909

Vancouver

Holtsche MM, van Beek N, Hammers CM, Vorobyev A, Kasperkiewicz M, Schumacher N, et al. Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15909

BibTeX
@article{Holtsche2026,
  author = {Holtsche, Maike M and van Beek, Nina and Hammers, Christoph M and Vorobyev, Artem and Kasperkiewicz, Michael and Schumacher, Nina and Muck, Philip and Schmidt, Enno},
  title = {Adjuvant therapy of severe and/or refractory bullous pemphigoid with immunoadsorption – A prospective monocenter pilot study},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.15909}
}
Kostenlos starten →